Skip Navigation LinksHome > January 2010 - Volume 69 - Issue 1 > Clinical, Neuropathologic, and Biochemical Profile of the Am...
Journal of Neuropathology & Experimental Neurology:
doi: 10.1097/NEN.0b013e3181c6b84d
Original Articles

Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation

Guardia-Laguarta, Cristina BSc; Pera, Marta BSc; Clarimón, Jordi PhD; Molinuevo, José Luis MD; Sánchez-Valle, Raquel MD; Lladó, Albert MD; Coma, Mireia PhD; Gómez-Isla, Teresa MD; Blesa, Rafael MD; Ferrer, Isidre MD, PhD; Lleó, Alberto MD

Free Access
Article Outline
Collapse Box

Author Information

From the Neurology Department (CG-L, MP, JC, MC, TG-I, RB, A. Lleó), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; Institut de Neuropatologia, Servei Anatomia Patológica, IDIBELL-Hospital Universitari de Bellvitge, Facultat de Medicina, Universitat de Barcelona (IF); Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CG-L, JC, MC, TG-I, RB, IF, A. Lleó); Alzheimer's Disease and Other Cognitive Disorders Unit (JLM, RS-V, A. Lladó), Department of Neurology, Hospital Clínic, Barcelona, Spain.

Send correspondence and reprint requests to: Alberto Lleó, MD, Neurology Department, Hospital de la Santa Creu i Sant Pau. Avda. Sant Antoni Ma Claret 167, 08025 Barcelona, Spain; E-mail: alleo@santpau.es

This work was supported by Grant Nos. PI071137 (to A.L.) and PI080582 (to I.F.) from the Fondo de Investigación Sanitaria.

Collapse Box

Abstract

We report the clinical, pathologic, and biochemical characteristics of the recently described amyloid precursor protein (APP) I716F mutation. We present the clinical findings of individuals carrying the APP I716F mutation and the neuropathologic examination of the proband. The mutation was found in a patient with Alzheimer disease with onset at the age of 31 years and death at age 36 years and who had a positive family history of early-onset Alzheimer disease. Neuropathologic examination showed abundant diffuse amyloid plaques mainly composed of amyloid-β42 and widespread neurofibrillary pathology. Lewy bodies were found in the amygdala. Chinese hamster ovary cells transfected with this mutation showed a marked increase in the amyloid-β42/40 ratio and APP C-terminal fragments and a decrease in APP intracellular domain production, suggesting reduced APP proteolysis by γ-secretase. Taken together, these findings indicate that the APP I716F mutation is associated with the youngest age of onset for this locus and strengthen the inverse association between amyloid-β42/40 ratio and age of onset. The mutation leads to a protein that is poorly processed by γ-secretase. This loss of function may be an additional mechanism by which some mutations around the γ-secretase cleavage site lead to familial Alzheimer disease.

Back to Top | Article Outline

INTRODUCTION

The genes of amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) have been implicated in the pathogenesis of familial Alzheimer disease (FAD). Mutations in the PSEN1 gene represent the most common cause of FAD (1), and more than 175 mutations have been identified to date (www.molgen.ua.ac.be/ADMutations). Mutations in the APP gene are rare but provide insight into the pathogenesis of FAD. All APP pathogenic mutations are located either in the amyloid-β (Aβ) sequence or in the vicinity of a protease cleavage site that influences APP proteolysis by different mechanisms. The Swedish APP mutation, adjacent to the β-cleavage site, increases the production of total Aβ by enhancing APP cleavage by β-secretase (2, 3). APP mutations within the Aβ sequence (e.g. the Arctic and Iowa mutations) cause severe cerebral amyloid angiopathy or Alzheimer disease (AD) (4-8) by enhancing the tendency of the Aβ peptide to aggregate (7, 9) or by increasing its resistance to proteolytic degradation (10, 11). Mutations near the γ-secretase cleavage site such as the London (V717I, V717G), Indiana (V717F), and Florida (I716V) mutations lead to an increase in the amyloidogenic Aβ1-42 (12-17).

Amyloid precursor protein has been shown to be cleaved by γ-secretase through a series of sequential cleavage steps. First, there is ϵ-cleavage near the membrane-cytoplasm boundary, followed by γ-cleavage in the middle of the transmembrane domain (18). The ϵ-cleavage results in the release of an APP intracellular domain (AICD), whereas the γ-cleavage results in the generation of Aβ peptides (19-21). Several Aβ species consisting of 36 to 43 residues are generated and constitutively secreted. Aβ40 is the most predominant species, and although Aβ42 is a minor one, it predominates in the diffuse and mature plaques found in AD (22).

Most studies on APP mutations near γ-secretase cleavage site have focused on the ratio Aβ42/40 as the main mechanism by which these mutations exert their pathogenic effects (15, 17, 23). Here, we describe the clinical, neuropathologic, and biochemical characteristics of the recently described APP I716F mutation (24). This family shows the youngest age of onset for this locus, an aggressive clinical course, and severe neuropathologic phenotype. Biochemical experiments confirmed a marked increased in Aβ42/40 ratio and reduced APP proteolysis by γ-secretase.

Back to Top | Article Outline

MATERIALS AND METHODS

Neuropathologic Examination

The neuropathologic study was performed on formalin-fixed, paraffin-embedded samples, as previously described (25). Sections of frontal (Area 8), primary motor, primary sensory, parietal, temporal superior, temporal inferior, anterior cingulate, anterior insular, and primary and associative visual cortices, entorhinal cortex and hippocampus, caudate, putamen and pallidum, medial and posterior thalamus, subthalamus, nucleus basalis of Meynert, amygdala, midbrain (2 levels), pons, medulla oblongata, cerebellar cortex, and dentate nucleus were examined. Dewaxed sections (5-μm thick) were stained with hematoxylin and eosin and with Klüver-Barrera, or were processed for immunohistochemistry using the EnVision+ system peroxidase procedure (DAKO, Barcelona, Spain). After incubation with methanol and normal serum, the sections were incubated with 1 of the primary antibodies at 4°C overnight. Antibodies to glial fibrillary acidic protein (DAKO), Aβ (Boehringer, Barcelona, Spain), and ubiquitin (DAKO) were used at dilutions of 1:250, 1:50, and 1:200, respectively. Antibodies to Aβ1-40 and Aβ1-42 (a generous gift from Dr. Sarasa, Zaragoza, Spain) were used at dilutions of 1:50. Antibodies to α-synuclein (Chemicon, Barcelona, Spain) were used at a dilution of 1:3000. Monoclonal anti-phospho-tau AT8 (Innogenetics, Gent, Belgium) was diluted 1:50. Phospho-specific tau rabbit polyclonal antibodies Thr181, Ser199, Ser202, Ser214, Ser231, Ser262, Ser396, and Ser422 (all from Calbiochem, Torrey Pines, CA) were used at a dilution of 1:100 except for anti-phospho-tauThr181, which was used at a dilution of 1:250. Antibodies to 3R and 4R tau (Upstate, Millipore, Barcelona, Spain) were used at dilutions 1:800 and 1:50, respectively. TAR DNA binding protein was examined using a mouse monoclonal antibody (Abnova, Tebu-Bio, Barcelona, Spain) at a dilution of 1:1000, and a rabbit polyclonal antibody (Abcam, Cambridge, UK) at a dilution of 1:2000. Phospho-TAR DNA binding protein was studied by using a mouse monoclonal antibody at a dilution of 1:5000 and a rabbit polyclonal antibody at a dilution of 1:2500 (both from Cosmo Bio Co., Ltd., Koto-ku, Japan). The peroxidase reaction was visualized with 0.05% diaminobenzidine and 0.01% H2O2. Sections were counterstained with hematoxylin. Sections processed for phospho-tau immunohistochemistry were boiled in citrate buffer before incubation with the primary antibody. Sections processed for Aβ and α-synuclein were pretreated with 95% formic acid.

Back to Top | Article Outline
Cell Culture and Transfections

Chinese hamster ovary (CHO) cells were cultured in Dulbecco's Modified Eagle Medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum at 37°C with 5% CO2 in a tissue culture incubator. Cells were transfected using Fugene reagent (Invitrogen) according to the manufacturer's instructions.

Back to Top | Article Outline
Plasmid Construction

Mutated cDNA constructs encoding APP V717I and APP I716F were introduced in human wild-type APP 695 cDNA by site-directed mutagenesis (Stratagene, Cedar Creek, TX).

Back to Top | Article Outline
Aβ Enzyme-Linked Immunosorbent Assay

Conditioned medium was collected 24 hours after transfection. Human Aβ1-40 was measured by ELISA, as described (26). Briefly, antibody 6E10 (against Aβ1-17; Chemicon, Temecula, CA) was used as a capture antibody and a rabbit polyclonal Aβ1-40 (Chemicon) as a detection antibody. After incubation for 3 hours, wells were washed with PBS and a horseradish peroxidase-conjugated donkey anti-rabbit antibody (Jackson Laboratories, West Grove, PA) was added. Wells were washed with PBS, Quantablue reagent (Pierce, Rockford, IL) was added, and samples were read at 320 nm using a Victor3 Wallac plate reader (Perkin-Elmer, Waltham, MA). Human Aβ1-42 and Aβ1-x (as a measure of total Aβ) were detected using sensitive ELISA kits (Wako, Osaka, Japan, and IBL, Hamburg, Germany, respectively).

Back to Top | Article Outline
Membrane Preparations and Cell-Free AICD Generation Assay

For Western blot analysis of the APP C-terminal fragments (CTFs), cellular membranes were isolated from CHO cells transfected with wild-type, V717I, or I716F APP constructs, as described (27). For the brain samples, 100 to 200 mg of tissue was homogenized with the Proteo Extract Native Membrane Protein Extraction Kit (Calbiochem). Amyloid precursor protein intracellular domain was generated in vitro from membrane preparations of transfected CHO cells, as described (19). The samples were electrophoresed in 5% to 16% Tris-Tricine gels, transferred to 0.2-μm nitrocellulose membranes, and detected by immunoblotting with a rabbit anti-APP C-terminal (Sigma-Aldrich, St. Louis, MO) antibody.

Back to Top | Article Outline
γ-Secretase Activity

γ-Secretase activity in cell lysates was measured by a fluorometric activity Kit (R&D Systems, Minneapolis, MN).

Back to Top | Article Outline
Statistical Analysis

One-way analysis of variance was performed to analyze differences in Aβ levels, APP CTFs, and γ-secretase activity, followed by least significant difference post hoc analysis. Levene test was also performed to determine whether variances were equal.

Back to Top | Article Outline

RESULTS

Family History

The proband was a 33-year-old man who complained of a progressive history of forgetfulness and difficulties in concentrating, with the onset of symptoms at age 31 years (Fig. 1A). He had problems in remembering recent events and with abstract reasoning. Over the next 2 years, he showed difficulties planning, using utensils, and performing fine-hand sequences that interfered with his work as a gardener. He also displayed difficulties with the sense of direction, and as a result, he had to stop working and driving. Occasionally, he complained of irregular jerks in both arms. Neuropsychologic evaluation at the age of 33 years showed deficits in verbal and visual memory, attention, and calculating with marked motor and constructive apraxia. His Mini Mental State Examination score was 21 of 30. Brain magnetic resonance imaging at the age of 33 years showed bilateral atrophy in frontoparietal regions. 99mTc-Hexamethylpropyleneamine oxime brain perfusion single-photon emission computerized tomography showed hypoperfusion in both parietal regions (Fig. 1B). The patient continued to worsen and died at the age of 36 years. The father's proband had developed dementia at the age of 35 years. A brain biopsy at the age of 39 years showed abundant diffuse and neuritic plaques, amyloid angiopathy, and neurofibrillary tangles immunoreactive for phosphorylated tau. The diagnosis made was AD, and he died at the age of 41 years. We were unable to investigate family history of dementia because he had been adopted. The proband's sibling is cognitively normal and refused genetic testing. There was no other family history of dementia. Genetic screening of the coding regions of PSEN1, PSEN2, and APP genes in the proband disclosed an APP I716F mutation (Fig. 1C; [24]). APOE genotype was ϵ3ϵ3.

Figure 1
Figure 1
Image Tools
Back to Top | Article Outline
Neuropathologic Examination of the Proband

Neuropathologic evaluation showed global cerebral atrophy. Microscopic examination revealed extensive diffuse and neuritic perineuronal Aβ plaques, subpial deposits, and cerebral amyloid angiopathy. Neuritic plaques, composed mainly of Aβ1-40 and Aβ1-42, predominated in the entorhinal cortex, subiculum, hippocampus, amygdala, and inner region of the temporal and orbitofrontal cortex (Fig. 2A-C). In contrast, diffuse plaques, perineuronal plaques, and subpial Aβ deposits were mainly stained with antibodies to Aβ1-42 (Fig. 2D-F) and were present in most of the neocortex. Cerebral amyloid angiopathy affected small arteries, arterioles, and venules of the meninges and the brain (Fig. 2B); capillaries were spared. Neurofibrillary tangles and neuropil threads were present in large numbers in the entorhinal and transentorhinal cortices, hippocampus, amygdala, nucleus basalis of Meynert, septal nuclei, and the entire cerebral neocortex, including the primary sensory and motor areas (Fig. 2G, H). Neurofibrillary tangles were also present in selected nuclei of the brainstem, including the substantia nigra, motor ocular nuclei, locus ceruleus, and reticular formation of the pons and medulla oblongata. Dystrophic neurites containing hyperphosphorylated tau were abundant in the amygdala, hippocampus, and entorhinal cortex, corresponding to AD Stage VI of Braak. All of these structures were stained with AT8, other phospho-specific anti-tau antibodies, and with anti-4R (Fig. 2G), anti-3R (Fig. 2H), and anti-ubiquitin antibodies.

Figure 2
Figure 2
Image Tools

α-Synuclein immunoreactivity was observed in the amygdala in the form of large numbers of Lewy bodies and aberrant neurites (Fig. 2I). TAR DNA binding protein-immunoreactive inclusions were absent. Neuronal loss, astrocytic gliosis, and microgliosis were moderate in the cerebral neocortex but were more marked in the entorhinal and perirhinal cortex, subiculum, and amygdala. Astrocytes predominated in the inner cortical layers of the neocortex, plexiform layers of the hippocampus, and around neuritic plaques. Likewise, microglia were increased in number in the cerebral cortex and white matter and more abundantly around neuritic plaques.

Back to Top | Article Outline
Biochemical Effects of the APP I716F Mutation

We next investigated the effects of this mutation on APP processing in transfection studies using CHO cells. Quantitative analysis of the major Aβ species in the conditioned medium from APP I716F-transfected CHO cells showed increased (∼2-fold) Aβ42, reduced (∼0.5-fold) Aβ40, and total Aβ (∼0.5-fold) levels compared with those of wild-type APP (Fig. 3A). As a result, the Aβ42/40 ratio was markedly increased (∼4-fold) in cells transfected with the APP I716F mutation (Fig. 3B). Results were compared with cells transfected with the adjacent APP V717I mutation (13), which led to similar but milder effects. Membrane preparations from APP I716F- and V717I-transfected cells showed a marked increase (2- and 2.5-fold) in APP CTFs compared with that of wild-type APP (Fig. 4A). Interestingly, the levels of APP CTFs were higher in the proband's brain homogenates than in sporadic AD patients or young and elderly healthy controls (Fig. 4B). Incubation of membrane preparations from APP I716F- and V717I-transfected cells showed a reduced production of AICD and accumulation of CTFs (Fig. 4C). Finally, lysates from cells transfected with APP I716F or V717I mutations showed reduced γ-secretase activity assessed by a fluorogenic kit assay (Fig. 4D).

Figure 3
Figure 3
Image Tools
Figure 4
Figure 4
Image Tools
Back to Top | Article Outline

DISCUSSION

The APP I716F mutation had previously been described as an artificial mutation with extreme effects on the Aβ42/40 ratio (23, 28-30). Here, we describe the full clinical, neuropathologic, and biochemical profile of the recently reported APP I716F mutation (24). This FAD mutation is associated with the youngest age of onset for this locus (mean age of onset, 49 years [31]), supporting the strong inverse association between Aβ42/40 ratio and age of onset (17). Neuropathologic study of the proband's brain revealed atypical generalized and extensive Aβ deposition in the brain and cerebral blood vessels. Amyloid-β deposition formed neuritic plaques in the inner regions of the temporal lobe and large numbers of Aβ1-42-predominant diffuse plaques, perineuronal plaques, and subpial deposits in the neocortex. As in other families with APP mutations (32, 33), as well as in sporadic AD cases (34), Lewy bodies were observed in the amygdala, suggesting that α-synuclein pathology is downstream of Aβ1-42 deposition in these families. However, the reasons for such selective involvement are not known.

Biochemical characterization of this mutation extended previously described results (23, 28-30). The APP I716F mutation leads to a marked increase in Aβ42 and the Aβ42/40 ratio and reduced Aβ40 and Aβ1-x levels. As expected, the Aβ42/40 ratio was lower than other studies that used APP C99 (which is the direct substrate for γ-secretase) for transfection studies (23, 28, 29). As for other APP mutations located near the γ-secretase cleavage site (17, 35), we also showed that the APP I716F mutation led to a prominent accumulation of APP CTFs in transfected cells. Interestingly, APP CTFs were higher in the proband's brain homogenates than in sporadic AD patients and healthy controls. Although the availability of only a single brain sample precluded an in-depth analysis of APP processing in this kindred, this increase suggests that APP CTF accumulation is not an artifact in the cellular model. However, the increase in APP CTFs does not necessarily reflect reduced γ-secretase activity because it has been observed without concomitant reduction in Aβ secretion (36). Therefore, we cannot completely exclude the possibility that this accumulation may be partially due to impaired degradation. In any case, accumulation of APP CTFs has been shown to be neurotoxic and to cause neurodegeneration in vitro and in vivo (35, 37, 38), and we cannot exclude the possibility that this can also contribute to the neurodegeneration observed in this family.

We further demonstrated a reduced AICD generation in cells expressing the APP I716F mutation. Amyloid precursor protein intracellular domain results from the ϵ-cleavage of APP β-CTF that occurs near the membrane-cytoplasm boundary (19-21). This initial cleavage is followed by different γ-cleavage events toward the middle of the transmembrane domain to generate different Aβ species (18). The presence of cleavage sites at every 3 residues between the γ- and ϵ-cleavage fits well with an α-helical model (39-42). According to this model, the cleavage sites for Aβ49, Aβ46, Aβ43, and Aβ40 are aligned on the α-helical surface of the β-CTF molecule, whereas those for Aβ48, Aβ45, and Aβ42 are aligned on the other α-helical surface (39). Although we only measured the major secreted Aβ species, the reduction in γ- and ϵ-cleavage and APP CTF accumulation in our study suggests that the APP I716F mutant is poorly processed by γ-secretase. This is supported by a reduced activity measured by a fluorogenic assay. Taken together, our results suggest that a selective loss of function in APP proteolysis can be caused by an APP mutation. A similar loss-of-function mechanism has been proposed for PSEN mutations (43). Consistent with this notion, a FAD-associated PSEN1 mutation was shown to slow sequential intramembrane cleavage by γ-secretase and other GXGD-aspartyl proteases, resulting in longer cleavage products (44).

Overall, this family reveals that, although the Aβ42/40 ratio seems to be the best indicator of severity of the disease in patients with APP mutations, the reduced processing might also contribute to the disease process and suggests an additional mechanism by which some mutations around the γ-secretase cleavage site may lead to AD.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The authors thank the Hospital Clínic-University of Barcelona Brain Bank for providing human brain samples, and Carlos A. Saura, Carolyn Newey, and Magdalena Sastre for reviewing the manuscript.

Back to Top | Article Outline

REFERENCES

1. Lleo A, Berezovska O, Growdon JH, et al. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 2004;12:146-56

2. Citron M, Oltersdorf T, Haass C, et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 1992;360:672-74

3. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1992;1:345-47

4. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124-26

5. Van Broeckhoven C, Haan J, Bakker E, et al. Amyloid β-protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 1990;248:1120-22

6. Hendricks HT, Franke CL, Theunissen PH. Cerebral amyloid angiopathy: Diagnosis by MRI and brain biopsy. Neurology 1990;40:1308-10

7. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat Neurosci 2001;4:887-93

8. Grabowski TJ, Cho HS, Vonsattel JP, et al. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001;49:697-705

9. Fraser PE, Nguyen JT, Inouye H, et al. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid β-protein. Biochemistry 1992;31:10716-23

10. Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Aβ to physiologically relevant proteolytic degradation. Lancet 2003;361:1957-58

11. Morelli L, Llovera R, Gonzalez SA, et al. Differential degradation of amyloid-β genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem 2003;278:23221-26

12. Chartier-Harlin MC, Crawford F, Houlden H, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 1991;353:844-46

13. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6

14. Murrell J, Farlow M, Ghetti B, et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97-99

15. Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of Aβ 42(43). Hum Mol Genet 1997;6:2087-89

16. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid β-protein secreted by familial amyloid β-protein precursor (β APP717) mutants. Science 1994;264:1336-40

17. De Jonghe C, Esselens C, Kumar-Singh S, et al. Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability. Hum Mol Genet 2001;10:1665-71

18. Selkoe D, Kopan R. Notch and Presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003;26:565-97

19. Sastre M, Steiner H, Fuchs K, et al. Presenilin-dependent γ-secretase processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2001;2:835-41

20. Yu C, Kim SH, Ikeuchi T, et al. Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment γ. Evidence for distinct mechanisms involved in γ-secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem 2001;276:43756-60

21. Gu Y, Misonou H, Sato T, et al. Distinct intramembrane cleavage of the β-amyloid precursor protein family resembling γ-secretase-like cleavage of Notch. J Biol Chem 2001;276:35235-38

22. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ 42(43). Neuron 1994;13:45-53

23. Lichtenthaler SF, Wang R, Grimm H, et al. Mechanism of the cleavage specificity of Alzheimer's disease γ-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci U S A 1999;96:3053-58

24. Guerreiro RJ, Baquero M, Blesa R, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging 2009. In press

25. Clarimon J, Molina-Porcel L, Gomez-Isla T, et al. Early-onset familial Lewy body dementia with extensive tauopathy: A clinical, genetic, and neuropathological study. J Neuropathol Exp Neurol 2009;68:73-82

26. Guardia-Laguarta C, Coma M, Pera M, et al. Mild cholesterol depletion reduces amyloid-β production by impairing APP trafficking to the cell surface. J Neurochem 2009;110:220-30

27. Steiner H, Capell A, Pesold B, et al. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J Biol Chem 1998;273:32322-31

28. Lichtenthaler SF, Ida N, Multhaup G, et al. Mutations in the transmembrane domain of APP altering γ-secretase specificity. Biochemistry 1997;36:15396-403

29. Herl L, Thomas AV, Lill CM, et al. Mutations in amyloid precursor protein affect its interactions with presenilin/γ-secretase. Mol Cell Neurosci 2009;41:166-74

30. Tan J, Mao G, Cui MZ, et al. Effects of γ-secretase cleavage-region mutations on APP processing and Aβ formation: Interpretation with sequential cleavage and α-helical model. J Neurochem 2008;107:722-33

31. Lippa CF, Swearer JM, Kane KJ, et al. Familial Alzheimer's disease: Site of mutation influences clinical phenotype. Ann Neurol 2000;48:376-79

32. Lantos PL, Ovenstone IM, Johnson J, et al. Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene. Neurosci Lett 1994;172:77-79

33. Hardy J. Lewy bodies in Alzheimer's disease in which the primary lesion is a mutation in the amyloid precursor protein. Neurosci Lett 1994;180:290-91

34. Uchikado H, Lin WL, DeLucia MW, et al. Alzheimer disease with amygdala Lewy bodies: A distinct form of α-synucleinopathy. J Neuropathol Exp Neurol 2006;65:685-97

35. McPhie DL, Lee RK, Eckman CB, et al. Neuronal expression of β-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid-β and cytoplasmic domains. J Biol Chem 1997;272:24743-46

36. Capell A, Steiner H, Romig H, et al. Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch. Nat Cell Biol 2000;2:205-11

37. Oster-Granite ML, McPhie DL, Greenan J, et al. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci 1996;16:6732-41

38. Yankner BA, Dawes LR, Fisher S, et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989;245:417-20

39. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, et al. Longer forms of amyloid β-protein: Implications for the mechanism of intramembrane cleavage by γ-secretase. J Neurosci 2005;25:436-45

40. Funamoto S, Morishima-Kawashima M, Tanimura Y, et al. Truncated carboxyl-terminal fragments of β-amyloid precursor protein are processed to amyloid β-proteins 40 and 42. Biochemistry 2004;43:13532-40

41. Zhao G, Mao G, Tan J, et al. Identification of a new presenilin-dependent ζ-cleavage site within the transmembrane domain of amyloid precursor protein. J Biol Chem 2004;279:50647-50

42. Zhao G, Cui MZ, Mao G, et al. γ-Cleavage is dependent on ζ-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J Biol Chem 2005;280:37689-97

43. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 2007;8:141-46

44. Fluhrer R, Fukumori A, Martin L, et al. Intramembrane proteolysis of GXGD-type aspartyl proteases is slowed by a familial Alzheimer disease-like mutation. J Biol Chem 2008;283:30121-28

Cited By:

This article has been cited 3 time(s).

Neurobiology of Aging
MAPT H1 haplotype is associated with enhanced alpha-synuclein deposition in dementia with Lewy bodies
Colom-Cadena, M; Gelpi, E; Marti, MJ; Charif, S; Dols-Icardo, O; Blesa, R; Clarimon, J; Lleo, A
Neurobiology of Aging, 34(3): 936-942.
10.1016/j.neurobiolaging.2012.06.015
CrossRef
Acta Neuropathologica
Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
Pera, M; Alcolea, D; Sanchez-Valle, R; Guardia-Laguarta, C; Colom-Cadena, M; Badiola, N; Suarez-Calvet, M; Llado, A; Barrera-Ocampo, AA; Sepulveda-Falla, D; Blesa, R; Molinuevo, JL; Clarimon, J; Ferrer, I; Gelpi, E; Lleo, A
Acta Neuropathologica, 125(2): 201-213.
10.1007/s00401-012-1062-9
CrossRef
Journal of Biological Chemistry
beta-Amyloid Precursor Protein Mutants Respond to gamma-Secretase Modulators
Page, RM; Gutsmiedl, A; Fukumori, A; Winkler, E; Haass, C; Steiner, H
Journal of Biological Chemistry, 285(): 17798-17810.
10.1074/jbc.M110.103283
CrossRef
Back to Top | Article Outline
Keywords:

α-Synuclein; γ-Secretase; Alzheimer disease; Amyloid; APP mutations; Genetics

© 2010 American Association of Neuropathologists, Inc

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.